13 completed. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
| Phase 2 | 1 | Completed 1 |
Follow Migraine without Aura: new trials by email Literature Review of Migraine without Aura trials Research Report on Migraine without Aura
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine Dihydroergotamine, Placebo - Migraine, Migraine With Aura | Phase 3 | Completed | Satsuma Pharmaceuticals, Inc. | 1591 | 2021-06-30 | 2023-11-27 |
| A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Dihydroergotamine - Migraine, Migraine With Aura | Phase 3 | Completed | Satsuma Pharmaceuticals, Inc. | 482 | 2020-09-14 | 2023-07-03 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine Dihydroergotamine, Placebos - Migraine, Migraine With Aura | Phase 3 | Completed | Satsuma Pharmaceuticals, Inc. | 1201 | 2019-06-24 | 2023-06-29 |
| Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment Sumatriptan+Promethazine (SPr) - Migraine With Aura, Migraine Without Aura | Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | 350 | 2013-01-01 | 2013-07-30 |
| Candesartan Versus Propranolol for Migraine Prevention Candesartan, propranolol, placebo - Migraine Without Aura, Migraine With Aura | Phase 2 / Phase 3 | Completed | Norwegian University of Science and Technology | 72 | 2009-04-01 | 2013-12-24 |
| Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Maxalt 10mg MLT plus Caffeine 75mg, Maxalt 10mg MLT plus Placebo, Placebo + Placebo - Migraine With Aura, Migraine Without Aura | Phase 3 | Completed | Diamond Headache Clinic | 50 | 2007-04-01 | 2012-04-25 |
| TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) sumatriptan succinate / naproxen sodium, Placebo - Migraine, Without Aura | Phase 3 | Completed | GlaxoSmithKline | 679 | 2006-09-01 | 2016-12-16 |
| Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Laxymig ER (drug) - Migraine With Aura, Migraine Without Aura | Phase 3 | Completed | Lotus Pharmaceutical | 74 | 2004-11-01 | 2007-09-10 |
| Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection - Migraine Without Aura Prophylaxis | Phase 3 | Completed | Department of Medical Services Ministry of Public Health of Thailand | 128 | 2003-02-01 | 2019-02-18 |
| A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine topiramate, propranolol - Migraine, Common Migraine | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 786 | 2001-04-01 | 2010-11-19 |
| A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine topiramate - Migraine, Common Migraine | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 768 | 2001-03-01 | 2010-11-19 |
| A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine topiramate - Migraine, Common Migraine | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 763 | 2001-02-01 | 2010-11-17 |
| Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study Placebo, Eletriptan HBr 40 mg, Eletriptan HBr 80 mg - Migraine Without Aura, Migraine With Aura | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 971 | 2000-03-01 | 2021-01-27 |
Migraine with Aura (11) · Migraine Disorders (9) · Headache (3)
Brain Diseases (13) · Central Nervous System Diseases (13) · Headache Disorders (13) · Headache Disorders, Primary (13) · Nervous System Diseases (13) · Migraine Disorders (4) · Neurologic Manifestations (3) · Pain (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3)
Dihydroergotamine (3) · Topiramate (3) · Propranolol (2) · Botulinum Toxins, Type A (1) · Caffeine (1) · Naproxen (1) · Pharmaceutical Preparations (1) · Sumatriptan (1) · abobotulinumtoxinA (1) · candesartan (1) · eletriptan (1) · rizatriptan (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Satsuma Pharmaceuticals, Inc. (3) · Department of Medical Services Ministry of Public Health of Thailand (1) · Diamond Headache Clinic (1) · GlaxoSmithKline (1) · Lotus Pharmaceutical (1) · Norwegian University of Science and Technology (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Shahid Beheshti University of Medical Sciences (1)
United States (5) · Norway (2) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Iran (1) · Italy (1) · Netherlands (1) · Portugal (1) · Spain (1) · Sweden (1)
Detlef Albrecht, MD (3) · Frederick G Freitag, DO (1) · Lars J Stovner, Ph.D. (1) · Shuu-Jiun Wang, MD (1) · Siwaporn Chankrachang, MD (1)
PMID 14982912, PMID 15096395, PMID 15316798, PMID 23946318, PMID 24335848, PMID 39373843, PMID 41186275
2008 (1)